News

Deal Announcements

Gemin X Adds $8 Million New Venture Capital

Friday, August 6, 2010 5:33:00 AM PDT | VentureDeal Staff
Malvern, Pennsylvania  --  Gemin X Pharmaceuticals announced that it has raised $8 million in its fifth round of institutional venture capital investment.

Gemin X is developing small molecule cancer therapeutics based on the regulation of apoptosis - the body's natural ability to destroy injured or damaged cells.

Caxton Advantage Life Sciences Fund led the round, which also included Sanderling Ventures and other undisclosed investors. The company said it would use the funding proceeds to continue its clinical trials.

Email Page  Email Page | Print Page Print Page

Free Trial

Want unlimited access to the complete database with thousands of technology companies, VCs and transactions for only $25 per month?

Start your Free 14 Day Trial now – no obligation or credit card required.

Free 14 day trial. No Obligation. Click to Register.
Venturedeal Twitter Venturedeal Facebook Venturedeal Linkedin


PCI - Level1